home / stock / mdnaf / mdnaf news

MDNAF News and Press, Mandatum Pankki Oyj From 02/22/21

Stock Information
Company Name: Mandatum Pankki Oyj
Stock Symbol: MDNAF
Market: OTC
Website: medicenna.com
Menu
MDNAF MDNAF Quote MDNAF Short MDNAF News MDNAF Articles MDNAF Message Board
Get MDNAF Alerts

News, Short Squeeze, Breakout and More Instantly...
MDNAF - Medicenna to Present at the Cowen 41st Annual Healthcare Conference

TORONTO and HOUSTON, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna,&...
MDNAF - Medicenna to Present at the 10th Annual SVB Leerink Global Healthcare Conference

TORONTO and HOUSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medice...

MDNAF - Medicenna Reports Third Quarter Fiscal 2021 Financial Results and Operational Highlights

TORONTO and HOUSTON, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “Company") (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, today announced its financial results and operational highlights for the quarter ended December 31, 2020...

MDNAF - Medicenna Establishes At-the-Market Sales Facility

TORONTO and HOUSTON, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, announced today that it has entered into a sales agreement with SVB Leerin...
MDNAF - Medicenna Announces Oral Presentation at the 2nd Annual Glioblastoma Drug Development Summit

- Presentation taking place today , December 9 , 2020 at 10:50 AM ET TORONTO and HOUSTON, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology c...

MDNAF - Medicenna Hosting Key Opinion Leader Call on MDNA55 for the Treatment of Recurrent Glioblastoma Multiforme

-  Call will take place on Friday, December 11, 2020 at 11:00 AM ET TORONTO and HOUSTON, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, t...

MDNAF - Medicenna to Participate in Upcoming December Investor Conferences

TORONTO and HOUSTON, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Fahar Merchant, Ph.D., President and Chief Executive Officer of Medicenna, will ...
MDNAF - Medicenna Announces Upcoming Oral Presentations at the 2020 Society for Neuro-Oncology Annual Meeting

TORONTO and HOUSTON, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will be presenting two on-demand oral presentations as part of the 2020 Socie...

MDNAF - Medicenna Reports Second Quarter Fiscal 2021 Financial Results and Operational Highlights

TORONTO and HOUSTON, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA; TSX: MDNA), a clinical stage immuno-oncology company, today announced its financial results and operational highlights for the quarter ended Septembe...

MDNAF - Medicenna to Present at Upcoming Scientific and Investor Events in November

TORONTO and HOUSTON, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (Nasdaq: MDNA) (TSX: MDNA), a clinical stage immuno-oncology company, today announced that Fahar Merchant, Ph.D., President and Chief Executive Officer of Medicenna, will prese...
Previous 10 Next 10